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Abstract
Background: Mouse embryonic stem cells cultured in vitro have the ability to differentiate into
cells of the three germ layers as well as germ cells. The differentiation mimics early developmental
events, including vasculogenesis and early angiogenesis and several differentiation systems are being
used to identify factors that are important during the formation of the vascular system. Embryonic
stem cells are difficult to transfect, while downregulation of promoter activity upon selection of
stable transfectants has been reported, rendering the study of proteins by overexpression difficult.
Results: CCE mouse embryonic stem cells were differentiated on collagen type IV for 4–5 days,
Flk1+ mesodermal cells were sorted and replated either on collagen type IV in the presence of
VEGFA to give rise to endothelial cells and smooth muscle cells or in collagen type I gels for the
formation of vascular tubes. The activity of the CMV and β-actin promoters was downregulated
during selection of stable transfectants and during differentiation to the Flk1 stage, while the CMV
immediate enhancer/β-actin promoter in the pCAGIPuro-GFP vector led to 100% of stably
transfected undifferentiated and differentiated cells expressing GFP. To further test this system we
expressed syndecan-2 and -4 in these cells and demonstrated high levels of transgene expression
in both undifferentiated cells and cells differentiated to the Flk1 stage.
Conclusion: Vectors containing the CAG promoter offer a valuable tool for the long term
expression of transgenes during stem cell differentiation towards mesoderm, while the CMV and
β-actin promoters lead to very poor transgene expression during this process.
Background
Mouse embryonic stem (ES) cells are derived from the
inner cell mass (ICM) of the mouse blastocyst and retain
pluripotency when cultured in vitro in the presence of fac-
tors that inhibit differentiation, such as leukaemia inhibi-
tory factor (LIF). However, when these factors are
withdrawn, ES cells have the potential to differentiate into
ectodermal, mesodermal, endodermal and germ cell line-
ages (reviewed in [1]). ES cells can differentiate either in
suspension, forming embryoid bodies (EBs) or as two-
dimensional adhesion cultures, either in the presence of
feeder cells or extracellular matrix (ECM) molecules [1].
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The regulation of ES cell differentiation is currently under
intense study, not least for potential therapeutic use. One
important area of investigation is ES cell differentiation
either in EBs or in 2-dimensional culture, along pathways
recapitulating vasculogenesis and early angiogenesis
[2,3]. Related to this is delineation of functions for growth
factors, adhesion molecules and transcription factors in
the formation of the vasculature.
Elucidating the role of angiogenic factors during differen-
tiation often requires over-expression of wild type and
mutant proteins. Transfection of ES cells with plasmids
using traditional electroporation and lipofectamine-
based methods can be problematic [4-6]. Conflicting data
about the activity of different promoters in undifferenti-
ated ES cells have also been obtained, while several stud-
ies have suggested that transcriptional inactivation of
promoters occurs during selection of stably transfected
cells [7-9]. Another problem is obtaining stable transgene
expression through stem cell differentiation. Several stud-
ies have looked at the efficacy of promoters in plasmid
based vector systems with a view to obtaining high tran-
sient and stable expression in stem cells. For example, the
CAG promoter has been used to express transgenes in
undifferentiated ES cells as well as ES cells undergoing dif-
ferentiation towards neuronal, myogenic and mesoder-
mal cell types [10-12]. In the latter case a transfection
system was used (ES cells expressing polyoma large T anti-
gen and a vector with a polyoma virus origin of replica-
tion) leading to episomal propagation of the vector
carrying the transgene of interest [12]. Although episomal
plasmid propagation may lead to very high levels of trans-
gene expression due to a high copy number of plasmid per
cell, certain experiments may require lower levels of over-
expression that may be more physiologically relevant.
Here, we compare the promoter activity of the CMV,
chicken β-actin and CAG promoters in undifferentiated
murine embryonic CCE cells as well as during differentia-
tion to mesoderm. These cells are routinely used for differ-
entiation into mesodermal lineages [13] and do not
express the polyoma virus large T antigen allowing inte-
gration of transgenes into the host's genome. We demon-
strate that of these vector systems, only plasmids
containing the CAG promoter can be used for long term
expression of genes during differentiation of two dimen-
sional cultures of mouse embryonic CCE ES cells grown
on collagen substrates towards mesoderm.
Results and Discussion
Differentiation of mesodermal cell lineages from mouse 
CCE ES cells
Cells of a mesodermal/endothelial lineage were differen-
tiated from mouse CCE embryonic stem cells following
the protocol described in [13] (Fig. 1A). Undifferentiated
CCE cells expressed high levels of E-cadherin, SSEA-1 and
Pecam-1, which is consistent with previous data [14-16].
These cells did not express the mesodermal/endothelial
marker Flk1, the endothelial cell (EC) marker VE-cadherin
or the smooth muscle cell (SMC)/pericyte marker PDG-
FRβ (Fig. 1B, day 0). Differentiation was initiated by the
removal of LIF from the medium and the seeding of cells
on collagen type IV. Flk1 expression was observed on days
4–5 of differentiation, while elevated levels of PDGFRβ
were also noted at the same time. Expression of Pecam-1
was much reduced during differentiation and the levels of
E-cadherin and SSEA-1 also declined by day 5. VE-cad-
herin levels remained negligible during this 5 day differ-
entiation period (Fig. 1B).
Flk1+ cells from either day 4 or day 5 cultures were FACS
sorted and replated on collagen type IV-coated plates in
the presence of VEGFA for a further 3 days (Fig. 1A). Dou-
ble immunofluorescence microscopy for the EC markers
VE-cadherin or Pecam-1 and the SMC marker α-smooth
muscle actin (αSMA) (Fig. 1C, D) showed the presence of
EC sheets surrounded by SMCs. Differentiation into ECs
was VEGFA-dependent, as only αSMA+ cells were observed
in its absence (data not shown). When Flk1+ cells were
FACS sorted and plated in three dimensional collagen
type I gels in the presence of VEGFA for an additional 6
days, the formation of angiogenic sprouts was observed
(Fig. 1E, F). Tubular structures positive for the EC marker
Pecam-1 were surrounded by αSMA+ SMCs/pericytes (Fig.
1G, H). The formation of tubes was dependent on
VEGFA/Flk1 signalling, since no tubes formed in the
absence of VEGFA or when Flk1- cells were sorted and cul-
tured in the presence of VEGFA (data not shown). These
data are in agreement with previous studies [13,3] and
suggest that this differentiation protocol mimics aspects
of both vasculogenesis and early angiogenesis and is suit-
able for ectopic expression studies.
The CMV and β-actin promoters are not suitable for 
sustained expression of transgenes during CCE cell 
differentiation
High levels of transfection efficiency (80% +) of CCE cells
(Fig. 2A, B) were obtained with a modified lipofectamine
based protocol where suspended cells were transfected
with pEGFP-N1 [9]. This compared favourably with other
methods such as electroporation (70% transfection effi-
ciency; data not shown) and the standard lipofectamine
protocol (40% efficiency; data not shown). However the
longevity of GFP expression in transfected CCE cells was
poor. After 7 days in culture under antibiotic selection
very few fluorescing cells were evident (Fig. 2C, D) as
compared to cultures 2 days after transfection (Fig. 2A, B).
These results were confirmed by FACS analysis showing
that only 34–50% of undifferentiated cells surviving anti-
biotic selection expressed GFP (Fig. 2G, I), while a dra-
matic decrease in the transgene's expression was noted in
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ES cell differentiation into Flk1+ mesodermal, endothelial and smooth muscle cellsFigure 1
ES cell differentiation into Flk1+ mesodermal, endothelial and smooth muscle cells. A. Schematic showing the pro-
tocol for differentiation of CCE cells to mesodermal lineages. B. Expression of cell surface markers at day 0 and days 3–5 of dif-
ferentiation; cells were analysed by FACS for the markers shown. C-D. Flk1+ cells were plated on collagen type IV in the 
presence of VEGFA. Cells were double immunostained for VE-cadherin (green) and αSMA (red) (C) or PECAM-1 (green) and 
αSMA (red) (D). EC sheets were found surrounded by SMCs. E-F. Phase contrast micrographs of Flk1+ cells after FACS sorting 
and seeding into collagen type I gels in the presence of VEGFA for 6 days. Vascular tube structures are arrowed. G-H. Collagen 
I gels were sectioned and stained for Pecam-1 (green) and αSMA (red) and showed Pecam-1+ tubular structures (arrows) sur-
rounded by smooth muscle cells.
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stably transfected cells differentiated for 5 days on colla-
gen type IV to the Flk1 stage (Fig. 2H, I). It should be
noted that at this stage the pool of cells contain both
Flk1+ and Flk1- cells. The GFP cDNA in pEGFP-N1 is
under the control of the CMV promoter and it is not
uncommon for transcriptional inactivation of this pro-
moter to occur in certain cell types. To overcome this
problem we expressed GFP under the control of the
chicken β-actin promoter. GFP expression in differenti-
ated cells was again very low (Fig. 2I) and this promoter
offered no advantage over the CMV promoter.
Since a higher percentage of transiently transfected cells
expressed GFP compared to the stably transfected cells
(Fig. 2A–D), cells 2 days post transfection were used for
differentiation to test whether this would lead to more
GFP+ cells present at the Flk1 stage. However, the use of
transiently transfected cells resulted in no cells expressing
GFP on day 5 of differentiation (Fig. 2E, F). This suggested
that stable integration of the transgene into the host's
chromosome is required for its expression.
From the above studies it was evident that resistance
against antibiotic selection did not correlate with expres-
sion of the transgene of interest. Therefore, bicistronic vec-
tors having GFP as the reporter gene were tested, as they
would allow for easy identification and selection of cells
expressing the transgene of interest. CCE cells were trans-
fected with either the pIRES2-EGFP plasmid or pIRES2-
EGFP(β-actin), where the CMV promoter had been substi-
tuted for the chicken β-actin promoter. However, GFP
expression was not apparent in CCE cells transfected with
either plasmid even 1 day after transfection (Figure 3A).
Control cultures were transfected in parallel with pEGFP-
N1 and GFP+ cells were abundant in this case. The bicis-
tronic vectors were then transfected into fibroblasts to
The CMV promoter is down regulated in mouse embryonic CCE cells and during differentiation into mesodermFigure 2
The CMV promoter is down regulated in mouse embryonic CCE cells and during differentiation into meso-
derm. A-D. CCE cells were transfected with pEGFP-N1 and subjected to G418 selection 48 hours later. Cells expressing GFP 
are obvious 2 days after transfection (A, B) while few GFP positive cells remain 7 days post transfection (C, D). E-F. CCE cells 
were transfected with pEGFP-N1 and differentiation was initiated 2 days post transfection. No GFP+ cells were observed on 
day 5 of differentiation to the Flk1 stage (pool of containing both Flk1+ and Flk1- cells) when transient transfectants were used. 
G-I. CCE cells were transfected with pEGFP-N1 and placed under G418 selection 2 days post transfection. Undifferentiated 
cells (G, I) and cells differentiated to the Flk1 stage (H, I) were analysed by FACS for GFP expression 14–19 days post transfec-
tion. The data suggest that less than 50% of the undifferentiated cells express GFP, while this percentage declines during differ-
entiation to the Flk1 stage. Similar levels of GFP expression were obtained during differentiation of cells transfected with 
pLK444-GFP.
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check their functionality and fluorescing cells were
obtained from transfections with both pIRES2-EGFP and
pIRES2-EGFP(β-actin) (Fig. 3B).
The above data suggest that to obtain sustained transgene
expression in murine CCE cells and during differentiation
into mesoderm, alternative promoters to the CMV and the
chicken β-actin promoters are required. Furthermore, the
above promoters driving expression in a vector that con-
tains an IRES element were inactive in undifferentiated ES
cells, in agreement with previous reports [7].
Vectors containing the CAG promoter can be used to 
express transgenes in murine CCE cells and during 
differentiation into mesoderm
The CMV immediate enhancer/β-actin (CAG) promoter
has been shown to give higher levels of transgene expres-
sion in several cell lines compared to the CMV and β-actin
promoters [17]. Two different vectors containing the CAG
promoter were used. The first, pCAGIPuro is a bicistronic
vector, where a puromycin resistance gene follows the
IRES element. GFP was cloned into this vector to create
pCAGIPuro-GFP (Table 1). The pCAGGS plasmid is a
monocistronic vector with GFP expression also under the
control of the CAG promoter. The G418 resistance cas-
sette from vector pMC1neo polyA was cloned into
pCAGGS to create pCAGGSneo-GFP (Table 1).
CCE cells were transfected with pCAGIPuro-GFP and
selected for puromycin resistance. FACS analysis for GFP
expression showed that virtually 100% of either undiffer-
entiated (Fig. 4A) or cells differentiated to the Flk1 stage
(Fig. 4B) expressed high levels of GFP. Indeed, all of the
cells in these differentiated cultures consisting of both
Flk1+ and Flk1- cells were expressing GFP and this sug-
gests that the CAG promoter is active in both Flk1+ and
Flk1- cells. CCE cells were also transfected with the
pCAGGSneo-GFP vector and were selected for G418
resistance. When stable transfectants were analysed by
FACS, approximately 50% of either undifferentiated (Fig.
The CMV and chicken β-actin promoters cannot drive gene expression in bicistronic vectors transfected into CCE cellsFigure 3
The CMV and chicken β-actin promoters cannot drive gene expression in bicistronic vectors transfected into 
CCE cells. CCE cells (A) or rat embryo fibroblasts (B) were transfected with the bicistronic vectors pIRES2-EGFP and pIRES-
EGFP(β-actin) in which the CMV promoter had been substituted with the chicken β-actin promoter. GFP expression was not 
evident in CCE cells transfected with these vectors; GFP+ cells were only obtained when cells were transfected with pEGFP-
N1. In contrast GFP expression was apparent in fibroblasts transfected with all three constructs (B). Micrographs were 
obtained 24 hours after transfection.
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4C) or differentiated (Fig. 4D) cells were GFP+. While this
was a substantially lower percentage of positive cells than
that obtained with the pCAGIPuro-GFP vector, it was
much superior to the pEGFP-N1 and pLK444-GFP vectors,
particularly during differentiation (see Fig. 2I).
Table 1: Plasmids used in this study.
Plasmid Promoter Transgene/s IRES element Antibiotic resistance to
pEGFP-N1 CMV GFP No G418
pIRES2-EGFP CMV GFP Yes G418
pIRES2(β-actin) β-actin GFP Yes G418
pLK444-GFP β-actin GFP No G418
pCAGIPuro-GFP CAG GFP and Puromycin resistance Yes Puromycin
pCAGGSneo-GFP CAG GFP No G418
pCAGIPuro-sdc2/4 CAG Syndecan-2/4 Yes Puromycin
Sustained GFP expression in CCE cells during differentiation into mesoderm is obtained using the CAG promoterFigure 4
Sustained GFP expression in CCE cells during differentiation into mesoderm is obtained using the CAG pro-
moter. CCE cells were transfected with pCAGIPuro-GFP (A, B) or pCAGGSneo-GFP (C, D) and selected for puromycin or 
G418 resistance, respectively. FACS analysis was performed on undifferentiated CCE cells (A, C) and cells differentiated to the 
Flk1 stage (B, D)14–18 days posts transfection and GFP expression was compared in vectors expressing GFP (red) and empty 
vector (blue) transfected controls.
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Having shown that the pCAGIPuro vector could be used
to achieve sustained GFP expression during differentia-
tion of CCE cells to mesodermal cell types we tested this
vector system for its ability to express genes of biological
interest. The syndecans are type I transmembrane prote-
oglycans involved in cell adhesion, migration and growth
factor interactions [18]. In mammals there are four family
members and we analysed undifferentiated and differen-
tiating CCE cells for syndecan expression using RT-PCR.
Undifferentiated CCE cells expressed only syndecans-1
and -4 (Fig. 5A), while Flk1+ and Flk1- cells FACS sorted on
day 4 of differentiation expressed all four syndecans (Fig.
5B, C). We then decided to study syndecans-2 and -4 in
further detail as they have been implicated in playing a
role in the vascular system [19-23]. FACS analysis of
undifferentiated CCE cells confirmed that cell surface syn-
decan-4 is present in these cells whereas syndecan-2 is not
(Fig. 5D). It was only after differentiation that syndecan-2
appeared on the cell surface at low levels.
We then used the pCAGIPuro plasmid to express synde-
cans-2 and -4. Transfected cells were selected for puromy-
cin resistance and the cells were differentiated on collagen
type IV for 5 days. FACS analysis confirmed that high lev-
els of cell surface expression of both proteins was achieved
in undifferentiated as well as differentiated cells (Fig. 5D),
although overexpression of these receptors had no effect
on the percentage of Flk1+ cells obtained during differen-
tiation (Fig. 5E).
Conclusion
Here we optimised a differentiation system of ES cells into
Flk1+ mesodermal cells, ECs and SMCs and subsequently
used the cells to form angiogenic sprouts in vitro. We then
evaluated a number of plasmid vector systems for express-
ing transgenes during differentiation to Flk1+mesodermal
cells and found that vectors which utilise the CAG pro-
moter are most effective at driving gene expression and do
not compromise the ability of stem cells to differentiate.
The CAG promoter provides long term expression of
transgenes in these cells however the system is most effec-
tive when the cells can be put under a selective pressure to
express the transgene. For this reason bicistronic vectors
containing an antibiotic resistance gene offers the best
way of obtaining expression of transgenes during differen-
tiation into mesodermal Flk1+ cells. This is in contrast to
vectors containing the CMV and β-actin promoters which
gave very low levels of expression. This presents a very use-
ful tool for use in studies of angiogenesis and vasculogen-
esis.
Methods
Cell lines and culture conditions
CCE mES cells (StemCell Technologies) were grown in
flasks coated with 0.1% gelatin (StemCell Technologies)
in Dulbecco's Modified Eagle Medium (DMEM) (Stem-
Cell Technologies) supplemented with 15% foetal calf
serum (FCS) (StemCell Technologies), 100 µM 2-mercap-
toethanol (Invitrogen), 10 ng/ml LIF (StemCell Technol-
ogies), 2 mM glutamine (Invitrogen) and 100 µM MEM
non-essential amino acids (StemCell Technologies). The
CCE cells were maintained in a humidified incubator at
37°C and 5% CO2 in air. Rat embryo fibroblasts (REFs)
were cultured in alpha-Minimum Essential Medium
(αMEM; Cambrex) supplemented with 5% FCS (Cam-
brex).
Antibodies
The Flk1 (clone Avas12α; final concentration 50 µg/ml),
the Pecam-1 (clone MEC13.3; 5 µg/ml) and the VE-cad-
herin (clone 11D4.1; 50 µg/ml) antibodies were from BD
Pharmingen. The α smooth muscle actin (αSMA) anti-
body (1A4; 1 µg/ml) was from Sigma, the E-cadherin anti-
body (clone ECCD2; 20 µg/ml) was from Takara, Japan
and the PDGFRβ antibody (10 µg/ml) was a kind gift
from Dr W. Stallcup, Burnham Institute, La Jolla, Califor-
nia. R-Phycoerythrin-labelled SSEA-1 (clone 480; 4 µg/
ml) and syndecan-2 antibodies (clone M140; 10 µg/ml)
were from Santa Cruz. The polyclonal chicken anti-synde-
can-4 antibody (Harlan Sera-Lab, UK) was raised against
the N-terminal 20 amino acids of the mature human pro-
tein. Antibodies were affinity purified from plasma using
standard procedures. The secondary antibodies (Molecu-
lar Probes) used were: Alexa-488 labelled donkey anti-rat
IgG; Alexa-568 labelled goat anti-mouse IgG; Alexa-488
labelled goat anti-rabbit IgG; Alexa-488 labelled goat anti-
chicken IgY, with working concentrations of 10 µg/ml.
Flow cytometry analysis and sorting (FACS)
Cells were detached with cell dissociation buffer (Invitro-
gen) and stained in FACS buffer (0.5% BSA, 2 mM EDTA
in 1× PBS) at 4°C. For exclusion of dead cells, the nucleic
acid dye Topro-3 (0.1 µM; Molecular Probes) was used.
The cells were analysed by a four colour FACS Calibur
(BD) and data for 10,000 live cells were analysed by the
CellQuest software. Cells stained with secondary anti-
body only or empty vector transfected cells served as con-
trols for background fluorescence. The gate M1 was set to
include 1% of the control cells that exhibited the highest
fluorescence within the population and cells were consid-
ered to be positive when contained within the gate M1.
For FACS sorting, dead cells were excluded by propidium
iodide staining (0.5 µg/ml; Molecular Probes). Cell popu-
lations were sorted by FACS Diva (BD) and collected in
sterile tubes in 2 ml medium. Flk1+ cells were plated either
on collagen type IV-coated plates or in collagen type I gels.
Immunofluorescence microscopy
Cells on glass coverslips were fixed in acetone (-20°C) for
2 min. After washing in PBS, cultures were incubated with
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Ectopic expression of Syndecan-2 and -4 through differentiation of CCE cells to mesodermal lineagesFigure 5
Ectopic expression of Syndecan-2 and -4 through differentiation of CCE cells to mesodermal lineages. Undiffer-
entiated CCE cells (A) as well as Flk1+ (B) and Flk1- (C) cells FACS sorted on day 4 of differentiation were analysed by RT-PCR 
for syndecan expression. D. CCE cells were transfected with either pCAGIPuro-sdc2 or pCAGIPuro-sdc4 and were selected 
for puromycin resistance. FACS analysis was performed on undifferentiated and cells differentiated to the Flk1 stage as indi-
cated using antibodies against syndecan-2 and -4. In each analysis, the dotted black line denotes the relevant secondary anti-
body control, the blue line corresponds to cells transfected with pCAGIPuro empty vector and the red line are cells 
transfected with constructs containing syndecan-2 or-4 cDNA. E. Levels of Flk1 were measured on day 5 of differentiation in 
cells transfected with pCAGIPuro-sdc2, pCAGIPuro-sdc4 or empty vector control. Data from 5 independent experiments are 
shown, where a total of 9 flasks were analysed for each construct. The bars represent the standard deviation, and the results 
were analysed with repeated-measures ANNOVA, using Prism Graphpad 4.0, assuming Gaussian distribution. No statistical 
significance was observed for the difference in FLK1 expression in cells transfected with the different constructs.
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the appropriate concentration of primary antibody in PBS
for 1 h at 37°C. Secondary antibody incubation for 1 h at
37°C was followed by further washing in PBS and cover-
slips were mounted with Immuno-Fluor (MP Biomedi-
cals). Controls included staining with secondary antibody
only, while in double labelling experiments, controls
included incubation with one primary antibody and both
secondary antibodies. Inappropriate cross-reactivity was
minimal. Samples were examined on an Olympus Provis
AX module fluorescence microscope (objective: UPlan-
Apo 40× 1.0 oil). The images were collected using a SPOT
Insight Mono digital camera and were processed by
Adobe Photoshop 7.0.
ES cell differentiation into mesodermal, endothelial and 
smooth muscle cells
Differentiation of CCE cells first into Flk1+ mesodermal
cells and then into VE-cadherin+ ECs and αSMA+ SMCs
that were able to form angiogenic sprouts was achieved
following the protocol described in [13]. Micrographs
were taken on an Olympus DP50 microscope and digital
camera system. Images were processed using the View-
finder Lite software and Adobe Photoshop 7.0.
Three dimensional collagen type I cultures were fixed with
3.5% paraformaldehyde for 1 h at room temperature. The
samples were washed 3 × 15 min with PBS and were
released from the wells and embedded in an 8% gelatin
solution to provide rigidity. Fixation with paraformalde-
hyde was repeated for 1 h at room temperature. Excess gel-
atin was removed and samples were stored in 0.02%
Sodium Azide in 1× PBS at 4°C. Sections of 200 µm thick-
ness were prepared on a Micro-Cut H1200 vibrotome
(Bio-Rad). Sections were permeabilised with 0.1% Triton
X-100 for 1 h at room temperature, then washed 3 × 15
min with PBS. Primary antibodies against Pecam-1 and
αSMA were added at appropriate concentrations and
incubated overnight at 4°C. Sections were washed with
PBS, then incubated in secondary antibody for 5 h at
room temperature. After further extensive washing, sec-
tions were mounted onto slides using Gene Frame gaskets
(Advanced Biotechnologies) and were sealed with cover-
slips. The samples were examined on a Leica DM-IRBE
confocal microscope and images were processed using
Leica TCS-NT and Adobe Photoshop 7.0 software.
RNA extraction and RT-PCR
RNA extraction was performed with RNA-Bee (Tel-test,
inc., Texas, US) and reverse transcription was performed
using Superscript II (Invitrogen) according to the manu-
facturer's instructions. OligodT was used to initiate cDNA
synthesis and the syndecan gene specific primers are as
detailed in Table 2.
Vectors and Cloning
The pEGFP-N1 plasmid was from Clontech. The
pMC1neo PolyA plasmid was from Stratagene. The
pCAGGS plasmid was a kind gift from Dr C. Huxley [17],
Imperial College London. The pCAGIPuro vector was a
kind gift from Dr H. Niwa, Riken Centre for Developmen-
tal Biology, Japan (Table 1).
Full length syndecan-2 and -4 cDNA obtained from RT-
PCR of mouse brain was cloned into the EcoRI site of vec-
tor pCAGIPuro to create pCAGIPuro-sdc2 and pCAG-
IPuro-sdc4, respectively using the primers described in
Table 2.
Table 2: Primers used in this study.
Primer Sequence Purpose
SDC1for ATGAGACGCGCGGCGCTC RTPCR
SDC1rev GGCGTAGAACTCCTCCTGC RTPCR
SDC2for GCCTTGATGGCCTGTGTGTC RTPCR
SDC2rev GCATAAAACTCCTTAGTGGG RTPCR
SDC3for CGTGGCTGACGTAAGGACC RTPCR
SDC3rev CTCTAGTATGCTCTTCTGAA RTPCR
SDC4for CGAGAGACAGAGGTCATCGAC RTPCR
SDC4rev TGCGTAGAACTCATTGGTGG RTPCR
bactfor ATGGATGACGATATCGCTGCG RTPCR
bactrev CTAGAAGCATTTGCGGTGCAC RTPCR
SDC2ecoRIfor TATATAGAATTCGTAGGAGCCACATCCCTG SDC2 cloning
SDC2ecoRIrev TATATAGAATTCTTATGCATAAAACTCCTTAGTGG SDC2 cloning
SDC4ecoRIfor TATATAGAATTCGACTGGTTTGCGCTGTTGAA SDC4 cloning
SDC4ecoRIrev TATATAGAATTCTCATGCGTAGAACTCATTGGT SDC4 cloning
IRESdelfor GATATCCGCTAGCGCTACCGGACT Deletion of CMV promoter from pIRES2-EGFP
IRESdelrev ATGCATGGCGGTAATACGGT Deletion of CMV promoter from pIRES2-EGFP
GFPfor TATATAAAGCTTGCCACCATGGTGAGCAAG GFP cloning
GFPrev TATATAGGATCCATGATCTAGAGTCGCGGCC GFP cloning
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The GFP cDNA from pCAGGS was removed by EcoRI
digestion, the product was gel purified then ligated to the
EcoRI site of pCAGIPuro to create pCAGIPuro-GFP.
To insert the neomycin resistance cassette into the
pCAGGS vector, pMC1neo polyA was digested with SalI
and XhoI to release the neomycin resistance cassette,
which was then ligated into the SalI site of pCAGGS to cre-
ate pCAGGSneo-GFP.
For control purposes, the GFP cDNA was removed from
pCAGGS by restriction digest with the enzyme EcoRI to
create pCAGGS-ev. The neomycin resistance cassette from
pMC1neo PolyA was then ligated to the SalI site of
pCAGGS-ev to create pCAGGSneo-EV.
To create pIRES2-EGFP(β-actin), the EcoRI/SalI fragment
of pLK444 [24] containing the β-actin promoter was gel
purified and the overhangs were filled using Pfu polymer-
ase. To remove the CMV promoter from pIRES2-EGFP
(Clontech), PCR was performed using the primer pair
IRESdelfor and IRESdelrev (Table 2). The primers were
designed to yield a plasmid backbone of the pIRES2-EGFP
containing an EcoRV site in place of the CMV promoter
(pIRES2-EGFP-CMV). pIRES-EGFP-CMV was then cut
with EcoRV, dephosphorylated and ligated to the blunt-
ended β-actin fragment to generate pIRES2-EGFP(β-
actin).
To create pLK444-GFP, the EGFP cDNA was amplified by
PCR from pEGFP-N1 using the primer pair GFPfor and
GFPrev (Table 2). The PCR product was digested with
HindIII and BamHI and ligated to the HindIII/BamHI
sites of pLK444 to yield pLK444-GFP.
Transfection
For transfection in suspension, 150,000 CCE cells were
plated per well of a six-well plate 24 h prior to transfec-
tion. Cells were trypsinised and washed in serum free
DMEM. 1 µg DNA, 10 µl lipofectamine (Invitrogen) and
serum free DMEM to a final volume of 50 µl were added
to the cell pellet and incubated for 10 min at room tem-
perature before transfer to a well of a 6-well plate contain-
ing 3 ml culture medium (supplemented with FCS). Fresh
medium was added after 24 h. Fibroblasts were trans-
fected with lipofectamine following standard procedures.
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